Heparan sulfate proteoglycans undergo differential expression alterations in right sided colorectal cancer, depending on their metastatic character

BMC Cancer

Volumn 15, Issue 1, 2015, Pages 1-20

  Fernández Vega, Iván ^a   García Suárez, Olivia ^b   García, Beatriz ^b,c   Crespo, Ainara ^d   Astudillo, Aurora ^c,e   Quirós, Luis M ^b,c  

^a HOSPITAL TXAGORRITXU   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

^c DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^d NEIKER and a Vaccine producing Commercial Company CZVSL   (Spain)

^e University Hospital   (Spain)

Author keywords

Chondroitin sulfate; Colorectal cancer; Glycosaminoglycan; Heparan sulfate; Proteoglycan

Indexed keywords

PROTEOHEPARAN SULFATE; RNA;

AGED; ANIMAL; BIOSYNTHESIS; COLORECTAL TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METASTASIS; REAL TIME POLYMERASE CHAIN REACTION; SECONDARY; TUMOR CELL CULTURE;

AGED; ANIMALS; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM METASTASIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 84944688624     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1724-9     Document Type: Article

References (89)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Manne U, Shanmugam C, Katkoori VR, Bumpers VR, Grizzle WE. Development and progression of colorectal neoplasia. Cancer Biomark. 2010;9:235-65.
3. Richman S, Adlard J. Left and right sided large bowel cancer. BMJ. 2002;324:931-2.
4. Chau BN, Diaz RL, Saunders MA, Cheng C, Chang AN, Warrener P, et al. Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analyses. Cancer Res. 2009;69:1368-74.
5. Baraz L, Haupt Y, Elkin M, Peretz T, Vlodaysky I. Tumor suppressor p53 regulates heparanase gene expression. Oncogene. 2006;25:3939-47.
6. Truant S, Bruyneel E, Gouyer V, De Wever O, Pruvot FR, Mareet M, et al. Requirement of both mucins and proteoglycans in cell-cell dissociation and invasiveness of colon carcinoma HT-29 cells. Int J Cancer. 2003;104:683-94.
7. Rider CC. Heparin/heparan sulphate binding in the TGF-beta cytokine superfamily. Biochem Soc Trans. 2006;34:458-60.
8. Lai JP, Oseini AM, Moser CD, Yu C, Elsawa SF, Hu C, et al. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. Hepatology. 2010;52:1680-9.
9. Sakane H, Yamamoto H, Matsumoto S, Sato A, Kikuchi A. Localization of glypican-4 in different membrane microdomains is involved in the regulation of Wnt signaling. J Cell Sci. 2012;125:449-60.
10. Zhao W, McCallum SA, Xiao Z, Zhang F, Linhardt RJ. Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides. Biosci Rep. 2012;32:71-81.
11. Mahtouk K, Cremer FW, Rème T, Jourdan M, Baudard M, Moreaux J, et al. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene. 2006;25:7180-91.
12. Maglietta R, Liuzzi VC, Cattaneo E, Laczko E, Piepoli A, Panza A, et al. Molecular pathways undergoing dramatic transcriptomic changes during tumor development in the human colon. BMC Cancer. 2012;12:608.
13. Esko JD, Lindahl U. Molecular diversity of heparan sulphate. J Clin Invest. 2001;108:169-73.
14. Whitelock JM, Iozzo RV. Heparan sulfate: a complex polymer charged with biological activity. Chem Rev. 2005;105:2745-64.
15. Park PW, Reizes O, Bernfields M. Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters. J Biol Chem. 2000;275:29923-6.
16. Sanderson RD. Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol. 2001;12:89-98.
17. García-Suárez O, Fernández-Vega I, Quirós LM. Multiple alterations of heparan sulfate in cancer. OA Cancer. 2013;1:1.
18. Park H, Kim Y, Lim Y, Han I, Oh ES. Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem. 2002;277:29730-6.
19. Bouziges F, Simon-Assmann P, Leberquier C, Marescaux J, Bellocq JP, Haffen K, et al. Changes in glycosaminoglycan synthesis and in heparan sulfate deposition in human colorectal adenocarcinomas. Int J Cancer. 1990;46:189-97.
20. Jayson GC, Lyon M, Paraskeva C, Turnbull JE, Deakin JA, Gallagher JT. Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem. 1998;273:51-7.
21. Karibe T, Fukui H, Sekikawa A, Shiratori K, Fujimori T. EXTL3 promoter methylation down-regulates EXTL3 and heparan sulphate expression in mucinous colorectal cancers. J Pathol. 2008;216:32-42.
22. Miyamoto K, Asada K, Fukutomi T, Okochi E, Yagi Y, Hasegawa T, et al. Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Oncogene. 2003;22:274-80.
23. Schefe JH, Lehmann KE, Buschmann IR, Unger T, Funke-Kaiser H. Quantitative real-time RT-PCR data analysis: current concepts and the novel "gene expression's CT difference" formula. J Mol Med. 2006;84:901-10.
24. Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol. 2011;3:1-34.
25. Kolset SO, Tveit H. Serglycin-structure and biology. Cell Mol Life Sci. 2008;65:1073-85.
26. Carlsson P, Kjellén L. Heparin biosynthesis. Handb Exp Pharmacol. 2012;207:23-41.
27. Kreuger J, Kjellén L. Heparan sulfate biosynthesis: regulation and variability. J Histochem Cytochem. 2012;60:898-907.
28. Nairn AV, Kinoshita-Toyoda A, Toyoda H, Xie J, Harris K, Dalton S, et al. Glycomics of Proteoglycan Biosynthesis in Murine Embryonic Stem Cell Differentiation. J Proteome Res. 2007;6:4374-87.
29. Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I. The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metast Rev. 2011;30:253-68.
30. Raman K, Kuberan B. Chemical Tumor Biology of Heparan Sulfate Proteoglycans. Curr Chem Biol. 2010;4:20-31.
31. Theocharis A, Skandalis SS, Tzanakakis GN, Karamanos NK. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 2010;277:3904-23.
32. Arvatz G, Barash U, Nativ O, Ilan N, Vlodaavsky I. Post-transcriptional regulation of heparanase gene expression by a 3' AU-rich element. FASEB J. 2010;24:4969-76.
33. Grobe K, Esko JD. Regulated translation of heparan sulfate N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymes by structured 5'-untranslated regions and internal ribosome entry sites. J Biol Chem. 2002;277:30699-706.
34. Yeaman C, Rapraeger AC. Post-transcriptional regulation of syndecan-1 expression by cAMP in peritoneal macrophages. J Cell Biol. 1993;122:941-50.
35. Day RM, Hao X, Ilyas M, et al. Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch. 1999;434:121-5.
36. Peretti T, Waisberg J, Mader AM, de Matos LL, da Costa RB, Conceicao GM, et al. Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma. Eur J Gastroenterol Hepatol. 2008;20:756-65.
37. Hashimoto Y, Skacel M, Adams JC. Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer. 2008;8:185.
38. Mitselou A, Skoufi U, Tsimogiannis KE, Briasoulis E, Vougiouklakis T, Arvanitis D, et al. Association of syndecan-1 with angiogenesis-related markers, extracellular matrix components, and clinicopathological features in colorectal carcinoma. Anticancer Res. 2012;32:3977-85.
39. Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, et al. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer. 2000;88:12-20.
40. Szatmári T, Dobra K. The Role of Syndecan-1 in Cellular Signaling and its Effects on Heparan Sulfate Biosynthesis in Mesenchymal Tumors. Front Oncol. 2013;3:310.
41. Filmus J, Capurro M, Rast J. Glypicans. Genome Bio. 2008;9:224.
42. Suhovskih AV, Mostovich LA, Kunin IS, Boboev MM, Neopmnyashchikh GI, Aidagulova SV, et al. Proteoglycan expression in normal human prostate tissue and prostate cancer. ISRN Oncol. 2013;2013:680136.
43. Su G, Meyer K, Nandini CD, Qiao D, Salamat S, Friedl A. Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells. Am J Pathol. 2006;168:2014-206.
44. Kleeff J, Ishiwata T, Kumbasar A, Friess H, Büchler MW, Korc M. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest. 1998;102:1662-7.
45. Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 2001;61:5562-9.
46. García-Suárez O, García B, Fernández-Vega I, Astudillo A, Quirós LM. Neuroendocrine tumors show altered expresión of chondroitin sulfate, glypican 1, glypican 5, and syndecan 2 depending on their differentiation grade. Front Oncol. 2014;4:15.
47. Fico A, Maina F, Dono R. Fine-tuning of cell signalling by glypicans. Cell Mol Life Sci. 2011;68:923-9.
48. Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, Chen Y, et al. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res. 2007;13:1133-9.
49. Lau CS, Yu CB, Wong HK, Fan DS, Wong KW, Lam DS, et al. Allelic imbalance at 13q31 is associated with reduced GPC6 in Chinese with sporadic retinoblastoma. Br J Ophthalmol. 2010;94:357-62.
50. Campos-Xavier AB, Martinet D, Bateman J, Belluoccio D, Rowley L, Tan TY, et al. Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair endochondral ossification and cause recessive omodysplasia. Am J Hum Genet. 2009;84:760-70.
51. Yiu GK, Kaunisto A, Chin YR, Toker A. NFAT promotes carcinoma invasive migration through glypican-6. Biochem J. 2011;440:157-66.
52. Cooper DL, Dougherty GJ. To metastasize or not? Selection of CD44 splice sites. Nat Med. 1995;1:635-7.
53. Kuniyasu H, Oue N, Tsutsumi M, Tahara E, Yasui W. Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3. Clin Cancer Res. 2001;7:4067-72.
54. Hempel N, How T, Dong M, Murphy S, Fileds TA, Blobe GC. Loss of betaglycan expression in ovarian cancer: role in motility and invasión. Cancer Res. 2007;67:5231-8.
55. Bernabeu C, Lopez-Novoa JM, Quintanilla M. The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta. 2009;1792:954-73.
56. Criswell TL, Dumont N, Barnett JV, Arteaga CL. Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Res. 2008;68:7304-12.
57. Woszczyk D, Gola J, Jurzak M, Mazurek U, Mykata-Ciesla J, Wilczok T. Expression of TGF beta1 genes and their receptor types I, II, and III in low- and high-grade malignancy non-Hodgkin's lymphomas. Med Sci Monit. 2004;10:33-7.
58. Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, Lepre J, et al. Identification of a global gene expression signature of B-chronic lymphocytic leucemia. Mol Cancer Res. 2003;1:346-61.
59. Iozzo RV, Zoeller JJ, Nyström A. Basement membrane proteoglycans: modulators Par Excellence of cancer growth and angiogenesis. Mol Cells. 2009;27:503-13.
60. Xinnong J, Couchman J. Perlecan and tumor angiogenesis. J Histochem Cytochem. 2003;51:1393-410.
61. Nielsen JS, McNagny KM. Novel functions of the CD34 family. J Cell Sci. 2008;121:3683-92.
62. Li Q, Olsen BR. Increased angiogenic response in aortic explants of collagen XVIII/endostatin-null mice. Am J Pathol. 2004;165:415-24.
63. Korpetinou A, Skandalis SS, Labropoulou VT, Smirlaki G, Noulas A, Karamanos NK, et al. Serglycin: At the Crossroad of Inflammation and Malignancy. Front Oncol. 2014;3:327.
64. He L, Zhou X, Qu C, Tang Y, Zhang Q, Hong J. Serglycin (SRGN) overexpression predicts poor prognosis in hepatocellular carcinoma patients. Med Oncol. 2013;30:707.
65. Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, et al. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 2011;71:3162-72.
66. Korpetinou A, Skandalis SS, Moustakas A, Happonen KE, Tveit H, Prydz K, et al. Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells. PLoS One. 2013;8:10.
67. Iozzo RV. Heparan sulfate proteoglycans: intrincate molecules with intriguing functions. J Clin Invest. 2001;108:165-7.
68. Pönighaus C, Ambrosius M, Casanova JC, Prante C, Kuhn J, Esko JD, et al. Human xylosyltransferase II is involved in the biosynthesis of the uniform tetrasaccharide linkage region in chondroitin sulphate and heparan sulphate proteoglycans. J Biol Chem. 2007;282:5201-6.
69. Venkatesan N, Barré L, Magdalou J, Mainard D, Netter P, Fournel-Gigleux S, et al. Modulation of xylosyltransferase I expression provides a mechanism regulating glycosaminoglycan chain synthesis during cartilage destruction and repair. FASEB J. 2009;23:813-22.
70. Nadanaka S, Zhou S, Kagiyama S, Shoji N, Sugahara K, Sugihara K, et al. EXTL2, a member of EXT family of tumor suppressor, controls glycosaminoglycan biosynthesis in a xylose kinase-dependent manner. J Biol Chem. 2013;288:9321-33.
71. Mizumoto S, Ikegawa S, Sugahara K. Human genetic disorders caused by mutations in genes encoding biosynthetic enzymes for sulfated glycosaminoglycans. J Biol Chem. 2013;288:10953-61.
72. Kalathas D, Theocharis DA, Bounias D. Chondroitin synthases I, II, III and chondroitin sulfate glucuronyltransferase expression in colorectal cancer. Mol Med Rep. 2011;4:363-8.
73. Joo EJ, Weyers A, Li G, Gasimli L, Li L, Choi WJ, et al. Carbohydrate-Containing Molecules as Potential Biomarkers in Colon Cancer. OMICS. 2014;18:231-41.
74. Iozzo RV, Bolender RP, Wight TN. Proteoglycan changes in the intercellular matrix of human colon carcinoma: an integrated biochemical and stereologic analysis. Lab Invest. 1982;47:124-38.
75. Grobe K, Ledin J, Ringvall M, Holmborn K, Forsberg E, Esko JD, et al. Heparan sulfate and development: differential roles of the N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymes. Biochim Biophys Acta. 2002;1573:209-15.
76. Kalathas D, Theocharis DA, Bounias D, Kyriakopoulou D, Papageorgakopoulou N, Stavropoulos MS, et al. Alterations of glycosaminoglycan disaccharide content and composition in colorectal cancer: structural and expressional Studies. Oncol Rep. 2009;22:369-75.
77. Smeds E, Habuchi H, Do AT, Hjertson E, Grundberg H, Kimata K, et al. Substrate specificities of mouse heparan sulphate glucosaminyl 6-O-sulphotransferases. Biochem J. 2003;372:371-80.
78. Thacker BE, Xu D, Lawrence R, Esko JD. Heparan sulfate 3-O-sulfation: A rare modification in search of a function. Matrix Biol. 2014;30:60-72.
79. Tátrai P, Egedi K, Somorácz A, van Kuppevelt TH, Ten Dam G, Lyon M, et al. Quantitative and qualitative alterations of heparan sulphate in fibrogenic liver diseases and hepatocellular cancers. J Histochem Cytochem. 2010;58:429-41.
80. Wade A, Robinson AE, Engler JR, Petrisch C, James CD, Phillips JJ. Proteoglycans and their roles in brain cancer. FEBS J. 2013;280:2399-417.
81. Bui C, Ouzzine M, Talhaoui I, Sharp S, Prydz K, Coughtrie MW, et al. Epigenetics: methylation-associated repression of heparan sulfate 3-O-sulfotransferase gene expression contributes to the invasive phenotype of H-EMC-SS chondrosarcoma cells. FASEB J. 2010;24:436-50.
82. Fernández-Vega I, García O, Crespo A, Castañón S, Menéndez P, Astudillo A, et al. Specific genes involved in synthesis and editing of heparan sulphate proteoglycans show altered expression patterns in breast cancer. BMC Cancer. 2013;13:24.
83. Asimakopoulou AP, Theocharis AD, Tzanakakis GN, Karamanos NK. The biological role of chondroitin sulfate in cancer and chondroitin-based anticancer agents. In Vivo. 2008;22:385-9.
84. Theocharis AD, Theocharis DA. High-performance capillary electrophoretic analysis of hyaluronan and galactosaminoglycan-disaccharides in gastrointestinal carcinomas. Differential disaccharide composition as a possible tool-indicator for malignancies. Biomed Chromatogr. 2002;16:157-61.
85. Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I, et al. Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol. 2000;157:1167-75.
86. Nobuhisa T, Naomoto Y, Ohkawa T, Takaoka M, Ono R, Murata T, et al. Heparanase expression correlates with malignant potential in human colon cancer. J Cancer Res Clin Oncol. 2005;131:229-37.
87. Hermano E, Lerner I, Elkin M. Heparanase enzyme in chronic inflammatory bowel disease and colon cancer. Cell Mol Life Sci. 2012;69:2501-13.
88. Peerless Y, Simon E, Sabo E, Ben-Izhak O, Hershkovitz D. Normal colon tissue and colon carcinoma show no difference in heparanase promoter methylation. Exp Mol Pathol. 2013;94:309-13.
89. Levy-Adam F, Feld S, Cohen-Kaplan V, Shteingauz A, Gross M, Arvatz G, et al. Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem. 2010;285:28010-9.